Learn more about investing in Helex Bio

Our team will get back to you soon to follow up on your inquiry.
Lead Rounds?
Helex Bio
Making genetic diseases a thing of the past.
Website
helex.bio/
Poulami Chuadhuri, Ph.D., CEO
"We call ourselves the GPS for gene editing, because we really decide on that exact location where the guide RNA can make the cut for a safer therapy, a more efficient therapy, so that there are no more unintended cuts anywhere else in the genome."
It costs $2 billion to develop a new gene-editing therapy, and $2 million simply to treat one patient.

Helex Bio enables gene therapy companies to design gRNAs & simulate outcomes of CRISPR edits to bring effective therapies to market faster with our Helex Platform™. The Helex Platform™ guides gene therapy companies in target identification, design and validation of efficient and safe gRNAs for creating functional impact with minimal significant off-targets. Additionally, the platform simulates edit outcomes to reliably develop therapy protocols.

The Helex Platform™ is powered by intelligent data driven deep-learning modeling using extensive high throughput next generation sequencing data derived from CRISPR edits on human cell lines. Helex not only gives reliable predictions through the Helex Platform™, but validate them in-house using cell-based assays and next generation sequencing to support with proven experimental data for high degree of reliability.